We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo
WHX Labs Dubai 2026
Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Protein's Role Suggests Treatment for Thalassemia

By Biotechdaily staff writers
Posted on 27 Jun 2002
A protein called alpha hemoglobin stabilizing protein, AHSP, isolated from the blood has been shown to bind and stabilize the alpha globin subunit of hemoglobin preventing it from forming a precipitate that damages red blood cells. This research was reported in the June 13, 2002, issue of Nature.


An excess of unstabilized alpha globin characterizes the inherited blood disorder beta thalasssemia, which affects some 300,000 patients worldwide. "AHSP acts as a chaperone molecule, a chemical that helps another protein to fold or unfold,” said Dr. Mitchell Weiss from The Children's Hospital of Philadelphia (PA, USA; www.chop.edu). "Here it makes free alpha globin stable and prevents its deleterious effects.”

Investigators studied the role of ASHP by using a strain of mice that had been genetically engineered to lack the gene that produces AHSP. The mice developed the reticulocytosis and abnormal erythrocyte morphology that is typical of thalassemia.

The protective function of AHSP could explain why it is that some patients who carry the genetic trait for beta thalassemia have mild disease and few symptoms even though their bodies produce more alpha than beta globin. However, if AHSP does not function properly, the excess alpha globin precipitation may change milder or intermediate thalassemia into more severe disease.

Research efforts will now focus on methods to increase production of ASHP in patients with thalassemia. "If we can reduce the buildup of free alpha globin, we may be able to lower the dose of [blood] transfusion needed and improve patients' quality of life,” added Dr. Weiss.





Related Links:
Children's Hospital of Philadelphia

New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080

Latest BioResearch News

Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
27 Jun 2002  |   BioResearch

Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
27 Jun 2002  |   BioResearch

New Method Simplifies Preparation of Tumor Genomic DNA Libraries
27 Jun 2002  |   BioResearch